title: Bermekimab
text: # Bermekimab
  
  Bermekimab (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A). As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.
  
  Bermekimab is being developed by XBiotech Inc.
  
  